Drug intelligence / Profile preview

HGI-005

Development stage: Preclinical
Lead developer: Hemogen Therapeutic
Modality: Gene Therapies

Overview

HGI-005 is an investigational gene therapy being developed by Shenzhen Hemogen for the treatment of neurodegenerative diseases. Currently in the research and early R&D stage, the program is part of Hemogen's pipeline which focuses on leveraging omics technology to develop accessible gene therapies. While the specific molecular targets and mechanism of action have not been publicly disclosed, the therapy is intended to address underlying genetic or cellular drivers of neurodegeneration.

Targets

ARSA (Arylsulfatase A)

Beyond the preview

Go deeper on HGI-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HGI-005.

Explore the full profile